Comorbid Schizophrenia and Substance Abuse
The DOI matches its Crossref record.
Abstract
Article AbstractAt some point during their lives, manypatients with schizophrenia abuse substances. The co-occurrence of substanceuse leads to poorer long- and short-term outcomes in schizophrenia andcomplicates the treatment of both conditions. The primary substances of abuseamong schizophrenia patients are alcohol, cannabis, cocaine, and nicotine. Thispresentation describes the prevalence, outcomes, and basis for this comorbidity.A brief discussion about the neurobiology of schizophrenia explains howschizophrenia may create a biologic predisposition to substance abuse byaltering the brain reward system. The efficacy of possible treatments forcomorbid schizophrenia and substance abuse are weighed, including typical andatypical antipsychotics and psychosocial interventions, and a list of possibleadjunctive agents is provided. This CME activity is expired. For more CME activities, visit cme.psychiatrist.com. Find more articles on this and other psychiatry and CNS topics: The Journal of Clinical Psychiatry The Primary Care Companion for CNS Disorders
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Psychosocial Treatments for Schizophrenia
Mueser, K. T., Deavers, F., Penn, D. L., & Cassisi, J. E. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185620 · Cited by 402
Renoir, T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00045 · Cited by 107
A review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103
Medical comorbidity in patients with schizophrenia and alcohol dependence
Batki, S. L., Meszaros, Z. S., Strutynski, K., Dimmock, J. A., Leontieva, L., Ploutz-Snyder, R., Canfield, K., & Drayer, R. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.016 · Cited by 72
“3 times greater compared to the general population (Regier et al., 1990; Green and Brown, 2006).”
InfluentialDias, R. S., Lafer, B., Russo, C., Del Debbio, A., Nierenberg, A. A., Sachs, G. S., & Joffe, H. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09121816 · Cited by 70
Paroxetine: current status in psychiatry
Pae, C.-U., & Patkar, A. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.2.107 · Cited by 53
Murata, Y., Kobayashi, D., Imuta, N., Haraguchi, K., Ieiri, I., Nishimura, R., Koyama, S., & Mine, K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c8ae80 · Cited by 37
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
“There is weak evidence derived from small retrospective studies that clozapine may have some benefit in the treatment of schizophrenia with comorbid substance use disorder, resulting in a reduction of alcohol consumption due to inhibition of dysfunctional brain reward circuits (Drake et al., 2000; Green, 2006; Kim et…”
BackgroundCharacteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study
Yasui-Furukori, N., Hashimoto, K., Tsuchimine, S., Tomita, T., Sugawara, N., Ishioka, M., & Nakamura, K. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000139 · Cited by 13
Nocturnal Enuresis After Paroxetine Abrupt Discontinuation: A Case Report
Polimeni, G., Grugno, R., Cordici, F., Vitetta, A., Caputi, A. P., & Bramanti, P. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181850bc2 · Cited by 6
Metadata
- Authors
- Green, A. I., & Brown, E. S.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-09-15
- Volume
- 67
- Issue
- 09
- Pages
- e08
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2038398639
- Cited by
- 112
- References
- 0
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.